Immune globulin therapy and kidney disease: Overview and screening, monitoring, and management recommendations

por Kobayashi, Roger H, Rigas, Michael T
Publicado 2022

Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome

por Melamed, Isaac, Kobayashi, Roger H., O'Connor, Maeve, Kobayashi, Ai Lan, Schechterman, Andrew, Heffron, Melinda, Canterberry, Sharon, Miranda, Holly, Rashid, Nazia
Publicado 2021

Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects...

por Wasserman, Richard L., Lumry, William, Harris, James, Levy, Robyn, Stein, Mark, Forbes, Lisa, Cunningham-Rundles, Charlotte, Melamed, Isaac, Kobayashi, Ai Lan, Du, Wei, Kobayashi, Roger
Publicado 2016

Dried Blood Spots, an Affordable Tool to Collect, Ship, and Sequence gDNA from Patients with an X-Linked Agammaglobulinemia Phenotype Residing in a Developing Country

por Segundo, Gesmar R. S., Nguyen, Anh T. V., Thuc, Huyen T., Nguyen, Le N. Q., Kobayashi, Roger H., Le, Hai T., Le, Huong T. M., Torgerson, Troy R., Ochs, Hans D.
Publicado 2018

Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies

por Kobayashi, Roger H., Gupta, Sudhir, Melamed, Isaac, Mandujano, J. Fernando, Kobayashi, Ai Lan, Ritchie, Bruce, Geng, Bob, Atkinson, Thomas Prescott, Rehman, Syed, Turpel-Kantor, Eva, Litzman, Jiří
Publicado 2019

Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficien...

por Kobayashi, Roger H., Gupta, Sudhir, Melamed, Isaac, Mandujano, J. Fernando, Kobayashi, Ai Lan, Ritchie, Bruce, Geng, Bob, Atkinson, Thomas Prescott, Rehman, Syed, Turpel-Kantor, Eva, Litzman, Jiří
Publicado 2022

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study

por Borte, Michael, Melamed, Isaac R., Pulka, Grazyna, Pyringer, Barbara, Knutsen, Alan P., Ochs, Hans D., Kobayashi, Roger H., Kobayashi, Ai Lan, Gupta, Sudhir, Strach, Magdalena, Smits, William, Pituch-Noworolska, Anna, Moy, James N.
Publicado 2017

Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig(®)) in the treatment of patients with primary immunodeficiencies

por Kobayashi, Roger H, Litzman, Jiří, Melamed, Isaac, Mandujano, J Fernando, Kobayashi, Ai Lan, Ritchie, Bruce, Geng, Bob, Atkinson, T Prescott, Rehman, Syed, Höller, Sonja, Turpel-Kantor, Eva, Kreuwel, Huub, Speer, J C, Gupta, Sudhir
Publicado 2022

Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens

por Gupta, Sudhir, DeAngelo, James, Melamed, Isaac, Walter, Jolan E., Kobayashi, Ai-Lan, Bridges, Tracy, Sublett, J. Wesley, Bernstein, Jonathan A., Koterba, Alan, Manning, Michael, Maltese, Joanna, Hoeller, Sonja, Turpel-Kantor, Eva, Kreuwel, Huub, Kobayashi, Roger H.
Publicado 2023